An innovative biotech SME developing plant-based enzyme treatments for antimicrobial resistant lung infections to improve health outcomes.

一家创新生物技术中小企业，开发植物酶疗法治疗耐药性肺部感染，以改善健康结果。

• 批准号: 10024335
• 金额: $ 44.42万
• 依托单位: INSPIRA PHARMACEUTICALS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10024335
• 关键词: innovative; biotech; SME; developing; plant

Inspira Pharmaceuticals Limited (Inspira) is a UK Biotechnology SME. It is developing a new drug candidate to treat bacterial biofilm formation in respiratory tract infections (RTIs). Lung biofilms hinder the ability of antibiotics and the body's immune system to overcome the infection. Higher doses of antibiotics are often required which leads to antimicrobial resistance (AMR). There are currently no treatments to specifically prevent or reduce biofilms and AMR infections are expected to be the leading cause of death globally by 2050\. Inspira's innovative drug candidate will be delivered by inhalation and is likely to be cheaper than antibiotics and able to be co-administered with other therapies.

Inspira Pharmaceuticals Limited（Insima）是英国生物技术中小型企业。它正在开发一种新的候选药物，以治疗呼吸道感染（RTIS）中细菌生物膜形成。肺生物膜阻碍了抗生素和人体免疫系统克服感染的能力。通常需要更高剂量的抗生素，从而导致抗菌素耐药性（AMR）。目前尚无治疗方法可以专门预防或减少生物膜，预计到2050年，全球死亡的主要原因\。 Inspira的创新药物候选人将通过吸入提供，并且可能比抗生素便宜，并且能够与其他疗法共同管理。